Get the Stockscreener App
1.94
0.00%
0.00
After Hours:
1.94
Alzamend Neuro Inc stock is traded at $1.94, with a volume of 91,015.
It is up +0.00% in the last 24 hours and up +24.36% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$1.94
Open:
$1.93
24h Volume:
91,015
Relative Volume:
0.65
Market Cap:
$9.36M
Revenue:
-
Net Income/Loss:
$-7.04M
P/E Ratio:
-0.4431
EPS:
-4.3784
Net Cash Flow:
$-6.17M
1W Performance:
+8.99%
1M Performance:
+24.36%
6M Performance:
+6.01%
1Y Performance:
-18.14%
1-Day Range:
$1.90
$1.94
1-Week Range:
$1.79
$1.94
52-Week Range:
$0.84
$2.68
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA
Compare ALZN vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.94 | 8.30M | 0 | -7.04M | -6.17M | -4.3784 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Alzamend Neuro Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Alzamend Neuro Flags Substantial Going-Concern Doubt After Q1 Loss Widens - minichart.com.sg
Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary - TradingView
Alzamend Neuro (ALZN) raises cash but says conditions raise doubt it can keep operating - Stock Titan
ALZN Q1'26 Earnings: revenue estimate is 0 USD - TradingView
Alzamend Neuro Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Alzamend Neuro (NASDAQ: ALZN) plans $25M preferred stock conversion vote - stocktitan.net
Anixa Biosciences Inc. (ANIX) Peer Comparison – Compare with Others - Value Research
Alzamend (ALZN) Results Versus Estimates: EPS Clears the Reported Estimate for the Current Session; Market Response: Shares Fall 4.29% in the Available RecordRevenue Guidance Range - vinanet.vn
IPO Databook: Alzamend Neuro (ALZN US)Aug 2026 - Smartkarma
Alzamend Neuro (ALZN) takes first step toward IPO with SEC filing - Stock Titan
Alzamend Neuro (ALZN) files amended insider trading report - Stock Titan
Alzamend’s lithium treatment data accepted for neuroscience meeting - Investing.com
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC - PR Newswire
Alzamend Neuro's AL001 fMRI abstract accepted for Neuroscience 2026 - scanx.trade
Alzamend (ALZN) Results Check: Reported EPS Tops Expectations for the Current Session; Market Reaction: Shares Move Higher 3.62% in the Current UpdateLong-Term Guidance - vinanet.vn
Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Alzamend (ALZN) Results at a Glance: Profit Per Share Clears Its Benchmark on the Day; Post-Earnings Trading - vinanet.vn
Alzamend to present lithium imaging data at Barcelona workshop By Investing.com - Investing.com Canada
Alzamend to present lithium imaging data at Barcelona workshop - Investing.com South Africa
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain - Investing News Network
Alzamend Neuro (ALZN) Advances 2.1% as Shares Hold Above $1.39 SupportDiagonal Spread Trade - vinanet.vn
ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline Remains CentralEarnings Preview - vinanet.vn
Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key SupportBreak of Structure - dars.gov.et
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - marketscreener.com
Alzamend Neuro secures $7.5M in initial funding tranche - Investing.com
Alzamend Neuro Secures $25 Million Preferred Stock Financing - TipRanks
Alzamend Neuro Secures Up to $25 Million Series D Preferred Financing; $7.5 Million Funded - TradingView
ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.47 Highlights Cost DisciplineEstimate Revision Count - vinanet.vn
Alzamend Neuro’s New Lithium Study Puts AL001 in the Bipolar Disorder Spotlight - TipRanks
ALZN|Alzamend Neuro Inc|Price:1.560|Chg%:-0.070 - TradingKey
Alzamend Neuro Inc reports results for the quarter ended April 30Earnings Summary - TradingView
TradingKey - TradingKey
Alzamend Neuro Inc (ALZN) Cash Flow - TradingKey
Alzamend Neuro Inc (ALZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alzamend Neuro, Inc. Revenue Breakdown – NASDAQ:ALZN - TradingView
Alzamend Neuro Inc (ALZN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ALZN Q2 2026 Earnings: EPS Beat Surprises Market as Stock RalliesQuarterly Profit Report - vinanet.vn
Alzamend Neuro Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Alzamend Neuro Announces Passing of Board Director - The Globe and Mail
Alzamend Neuro FY 2026: Revenue $0 EPS $(2.63) — 10-K Summary - TradingView
ALZN Q2 2026 Earnings: EPS Beat of 70.46% Surprise, No Revenue Reported, Stock Rises 1.52%EPS Consistency Score - dars.gov.et
Alzamend Neuro Announces Passing of Director Fahey McGrath, Ph.D. in July 2026 – SEC 8-K Filing Details 7 - Minichart
Price to sales forward of Alzamend Neuro, Inc. – BOATS:ALZN - TradingView
ALZN Q2 2026 Earnings: Narrower-than-expected loss sparks positive market reactionFiscal Year Earnings - dars.gov.et
ALZN Q2 2026 Earnings: EPS Beat by 70% but No Revenue – Stock Jumps on SurpriseGuidance Upgrade Report - dars.gov.et
$Alzamend Neuro (ALZN.US)$ it be like that - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
ALZN Q4'25 Earnings: EPS estimate is (0.67) USD - TradingView
Alzamend Neuro | DEF 14A: Definitive information statements - Moomoo
Alzamend Neuro, Inc. Actuals & Estimates (NASDAQ:ALZN) - TradingView
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alzamend Neuro Inc Stock (ALZN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Apr 14 '26 |
Buy |
1.00 |
108,388 |
108,897 |
116,648 |
| AULT MILTON C III | Director |
Dec 23 '25 |
Sale |
2.07 |
1,851 |
3,825 |
0 |
| Horne William B. | Director |
Dec 19 '25 |
Sale |
2.12 |
3,333 |
7,059 |
0 |
| McGrath Lynne Fahey | Director |
Oct 23 '25 |
Sale |
2.29 |
30 |
69 |
25 |
| AULT MILTON C III | Director |
Oct 08 '25 |
Sale |
2.44 |
101,394 |
247,158 |
28,657 |
| AULT MILTON C III | Director |
Oct 09 '25 |
Sale |
2.32 |
20,397 |
47,390 |
8,260 |
| AULT MILTON C III | Director |
Oct 06 '25 |
Sale |
2.45 |
82,033 |
201,268 |
26,227 |
| AULT MILTON C III | Director |
Oct 07 '25 |
Sale |
2.49 |
57,379 |
142,954 |
68,848 |
| AULT MILTON C III | Director |
Oct 03 '25 |
Sale |
2.44 |
65,903 |
160,889 |
8,260 |
| AULT MILTON C III | Director |
Oct 01 '25 |
Sale |
2.35 |
36,777 |
86,378 |
94,849 |
0.14%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):